Abate As Industries reported a consolidated net profit of ₹224.34 lakh for the quarter ended June 30, 2026, marking a 22% decline from ₹240.93 lakh in the corresponding period of FY25. Total revenue fell sharply by 44% to ₹2,307.29 lakh, down from ₹4,147.91 lakh year-ago, driven primarily by a contraction in revenue from operations which slipped to ₹2,281.82 lakh from ₹4,105.86 lakh.

The company’s standalone entity posted a profit of ₹14.31 lakh against ₹13.46 lakh in Q1FY25, with total revenue recorded at ₹25.05 lakh. The divergence between the modest standalone performance and the significant consolidated headwinds highlights the weight of subsidiary operations on the group’s overall financial health.

Board Approvals and Corporate Actions

During its meeting on August 13, 2026, the board approved the unaudited financial results for both standalone and consolidated entities, subject to limited review by statutory auditors Mahesh C Solanki & Co. The board also scheduled the 35th Annual General Meeting (AGM) for September 16, 2026.

Key personnel changes and strategic approvals included:

• New Appointment: Mr. Aboobaker Vattamkandathil was appointed as an Additional Director in the category of Non-Executive Independent Director, effective August 13, 2026.
• Reappointments: Dr. Muhammed Swadique was reappointed as Executive Director, while Ms. Julie G Varghese and Ms. Indu Kamala Ravindran were reappointed as Independent Directors. All terms are effective from August 14, 2026, or December 28, 2026, respectively, until August/December 2031, subject to member approval at the AGM.
• Strategic Expansion: The board proposed a special resolution to alter Clause III(A)(1) of the Memorandum of Association. This amendment aims to broaden the company’s scope to include establishing, operating, and managing multi-specialty hospitals, diagnostic centers, and digital healthcare platforms, signaling a pivot toward the integrated healthcare sector.

Financial Performance Overview

What the Numbers Show

The consolidated result reveals a significant compression in operational efficiency alongside the revenue drop. While revenue from operations declined by 44%, total expenses decreased by only 17% to ₹2,036.34 lakh from ₹3,915.62 lakh. This disparity indicates that fixed cost structures did not scale down proportionally with the sharp fall in top-line growth, pressuring margins.

Furthermore, tax expenses rose sharply to ₹48.49 lakh in Q1FY26 compared to ₹16.29 lakh in Q1FY25, despite the lower pre-tax profit of ₹272.83 lakh versus ₹240.93 lakh. This suggests a higher effective tax rate or changes in deferred tax provisions impacting the bottom line disproportionately to the earnings decline.

Abate As Industries Ltd has closed its trading window effective Wednesday, July 1, 2026, to comply with regulations ahead of its financial results for the quarter ended June 30, 2026. The window will remain shut until 48 hours after the announcement of the unaudited financial results for Q1FY26. This measure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading.

During this period, all directors, designated employees, insiders, and their immediate relatives are prohibited from entering into any transaction involving the securities of the company. The restriction ensures that no privileged information is utilized for trading purposes prior to the public disclosure of financial performance.

The trading window is scheduled to reopen 48 hours after the unaudited financial results for the quarter ending June 30, 2026, are declared to the stock exchanges. The specific date for the Board Meeting, where the results are likely to be considered, will be communicated by the company in a separate intimation.

Key Details

The closure is a standard procedural step implemented by listed companies to maintain market integrity and adhere to regulatory mandates during sensitive financial reporting periods.